December 2023

Advance Notice of Proposed Rulemaking: Controlled Substance Destruction Alternatives to Incineration - Extension of Comment Period (PDF) (December 20, 2023)

Joeseph Potter, D.D.S.; Decision and Order (PDF) (December 21, 2023)

Mark Young, M.D.; Decision and Order (PDF) (December 21, 2023)

Frank A. Hooper, D.V.M.; Decision and Order (PDF) (December 21, 2023)

Kinetochem LLC (PDF) (December 18, 2023)

Siegfried USA, LLC (PDF) (December 18, 2023)

AJNA BioSciences (PDF) (December 18, 2023)

Groff Health, Inc. (PDF) (December 18, 2023)

APEXX Pharmacy, LLC; Decision and Order (PDF) (December 15, 2023)

Gary R. Wisner, M.D.; Decision and Order (PDF) (December 15, 2023)

Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (December 13, 2023)

Final Rule: Specific Listing for Three Currently Controlled Schedule I Substances (PDF) (December 13, 2023)

Temporary Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB-4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA into Schedule I (PDF) (December 12, 2023)

Placement of Nine Specific Fentanyl-Related Substances in Schedule I (PDF) (December 7, 2023)

Element Materials Technology Santa Rosa (PDF) (December 4, 2023)

Caligor Coghlan Pharma Services (PDF) (December 4, 2023)

Restek Corporation (PDF) (December 4, 2023)

November

Pharmaron Manufacturing Services (US) LLC (PDF) (November 30, 2023)

Pharmaron Manufacturing Services (US) LLC (PDF) (November 30, 2023)

Navinta LLC (PDF) (November 24, 2023)

Organix Chemistry Solutions, LLC (PDF) (November 24, 2023)

Groff NA Hemplex LLC (PDF) (November 24, 2023)

Organic Standards Solutions International, LLC (PDF) (November 24, 2023)

Isosciences, LLC (PDF) (November 24, 2023)

VHG Labs DBA LGC Standards (PDF) (November 24, 2023)

Sigma Aldrich Research Biochemicals, Inc. (PDF) (November 24, 2023)

Noramco (PDF) (November 8, 2023)

Noramco (PDF) (November 8, 2023)

Curia Missouri, Inc. (PDF) (November 8, 2023)

Jagjit Kaleka, D.V.M.; Decision and Order (PDF) (November 7, 2023)

Groff NA Hemplex LLC (PDF) (November 7, 2023)

Mylan Technologies Inc. (PDF) (November 7, 2023)

Notice With Request for Comments: Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024 (PDF) (November 2, 2023)

Osmin A. Morales, M.D.; Decision and Order (PDF) (November 2, 2023)

Isaac Sved, M.D.; Decision and Order (PDF) (November 2, 2023)

Blue Mint Pharmacy; Decision and Order (PDF) (November 2, 2023)

October

Final Rule: Designation of Halides of 4-Anilinopiperidine as List I Chemicals (PDF) (October 31, 2023)

Interim Final Rule; Request for Comments: Placement of Zuranolone in Schedule IV (PDF) (October 31, 2023)

Proposed Rule: Controlled Substance Destruction Alternatives to Incineration (PDF) (October 31, 2023)

Dmitry Anatolevich Shelchkov, M.D.; Decision and Order (PDF) (October 31, 2023)

Siamak Arassi, M.D.; Decision and Order (PDF) (October 31, 2023)

Demille W. Madoux, M.D.; Decision and Order (PDF) (October 31, 2023)

Fares F. Yasin, M.D.; Decision and Order (PDF) (October 31, 2023)

Stephen E. Van Noy, P.A.; Decision and Order (PDF) (October 31, 2023)

Notice With Request for Comments: Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 (PDF) (October 31, 2023)

DEA Adds Precursor Chemicals Used to Make Illicit Fentanyl to the Special Surveillance List (October 30, 2023)

Proposed Amendment: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (PDF) (October 25, 2023)

Final Notice: Special Surveillance List of Chemicals, Products, Materials and Equipment Used in the Manufacture of Controlled Substances and Listed Chemicals (PDF) (October 24, 2023)

Nexus Pharmaceuticals, Inc. (PDF) (October 23, 2023)

Final Rule: Additions to Listing of Exempt Chemical Mixtures (PDF) (October 23, 2023)

Fresenius Kabi USA, LLC (PDF) (October 18, 2023)

Cayman Chemical Company (PDF) (October 18, 2023)

Chattem Chemicals, Inc. (PDF) (October 13, 2023)

Cambridge Isotope Laboratories, Inc. (PDF) (October 13, 2023)

Curia New York, Inc. (PDF) (October 13, 2023)

Cerilliant Corporation (PDF) (October 13, 2023)

Proposed Rule: Propionyl Chloride (PDF) (October 12, 2023)

Temporary Rule: Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (PDF) (October 10, 2023)

Fisher Clinical Services, Inc. (PDF) (October 4, 2023)

Final Order: Adjustment to the Aggregate Production Quota for Methylphenidate (for Sale) for 2023 (PDF) (October 3, 2023)

September

DEA Increases Production Quota to Manufacture Medication to Treat Attention Deficit Disorder (September 29, 2023)

Eli-Elsohly Laboratories (PDF) (September 29, 2023)

Maridose LLC (PDF) (September 29, 2023)

Curia Wisconsin, Inc. (PDF) (September 29, 2023)

VHG Labs dba LGC Standards (PDF) (September 29, 2023)

Restek Corporation (PDF) (September 29, 2023)

Restek Corporation (PDF) (September 29, 2023)

Cambridge Isotope Laboratories, Inc. (PDF) (September 29, 2023)

Proposed Rule: Placement of Ethylphenidate in Schedule I (PDF) (September 22, 2023)

60-Day Notice: Report of Theft or Loss of Controlled Substance and Report of Loss or Disappearance of Listed Chemicals (PDF) (September 20, 2023)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (September 15, 2023)

AMPAC Fine Chemicals Virginia LLC (PDF) (September 15, 2023)

Olon Ricerca Bioscience, LLC (PDF) (September 15, 2023)

Curia New York, Inc. (PDF) (September 15, 2023)

Experic LLC (PDF) (September 15, 2023)

Veterans Pharmaceuticals, Inc. (PDF) (September 15, 2023)

Cambrex High Point, Inc. (PDF) (September 15, 2023)

Benuvia Operations, LLC (PDF) (September 15, 2023)

PCI Synthesis (PDF) (September 15, 2023)

Green Wave Analytical Decision and Order (PDF) (September 14, 2023)

Rachel Pittala, APRN; Decision and Order (PDF) (September 14, 2023)

60-Day Notice: Controlled Substances Import/Export Declaration (PDF) (September 11, 2023)

60-Day Notice: Import/Export Declaration for List I and List II Chemicals (PDF) (September 11, 2023)

60-Day Notice: Application for Permit To Import Controlled Substances for Domestic and/or Scientific Purposes (PDF) (September 11, 2023)

60-Day Notice: Report of Loss or Disappearance of Listed Chemicals and Regulated Transactions in Tableting/Encapsulating Machines (PDF) (September 11, 2023)

60-Day Notice: Application for Permit To Export Controlled Substances, Application for Permit To Export Controlled Substances for Subsequent Reexport (PDF) (September 11, 2023)

August

TELEMEDICINE LISTENING SESSION (August 22, 2023)

DEA Hosts Public Listening Sessions on Telemedicine Regulations (August 7, 2023)

Pisgah Laboratories Inc. (PDF) (August 22, 2023)

Irvine Labs Inc. (PDF) (August 22, 2023)

Cambrex Charles City (PDF) (August 22, 2023)

Final Order: Placement of Metonitazene in Schedule I (PDF) (August 18, 2023)

Ndubuisi J. Okafor, M.D.; Decision and Order (PDF) (August 18, 2023)

William Tuong, M.D.; Decision and Order (PDF) (August 18, 2023)

FDA and DEA Joint Letter on Shortages in Prescription Stimulants (PDF) (August 1, 2023)

Curium US LLC (PDF) (August 17, 2023)

Vici Health Sciences, LLC (PDF) (August 17, 2023)

David H. Marcowitz, D.O.; Decision and Order (PDF) (August 14, 2023)

Weise Prescription Shop Inc.; Decision and Order (PDF) (August 14, 2023)

Olga Wildfeuer, M.D.; Decision and Order (PDF) (August 14, 2023)

Stephen K. Jones, M.D.; Decision and Order (PDF) (August 14, 2023)

Debora Ryder, N.P.; Decision and Order (PDF) (August 14, 2023)

Yogeshwar Gill, M.D.; Decision and Order (PDF) (August 14, 2023)

Continuus Pharmaceuticals (PDF) (August 10, 2023)

Caligor Coghlan Pharma Services (PDF) (August 10, 2023)

Chattem Chemicals (PDF) (August 10, 2023)

Chemtos, LLC (PDF) (August 9, 2023)

Cambrex Charles City (PDF) (August 9, 2023)

Cambrex High Point, Inc. (PDF) (August 9, 2023)

Catalent Pharma Solutions, LLC (PDF) (August 9, 2023)

Galephar Pharmaceutical Research, Inc. (PDF) (August 9, 2023)

Cerilliant Corporation (PDF) (August 9, 2023)

ANI Pharmaceuticals Inc. (PDF) (August 9, 2023)

Final Rule: Dispensing of Narcotic Drugs To Relieve Acute Withdrawal Symptoms of Opioid Use Disorder (PDF) (August 8, 2023)

Notice: Practice of Telemedicine: Listening Sessions (PDF) (August 7, 2023)

Final Rule: Implementation of the Designer Anabolic Steroid Control Act of 2014 (PDF) (August 1, 2023)

July

Final Rule: Transfer of Electronic Prescriptions for Schedules II-V Controlled Substances Between Pharmacies for Initial Filling (PDF) (July 27, 2023)

Temporary Amendment: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I (PDF) (July 26, 2023)

Veranova, L.P.; Correction (PDF) (July 24, 2023)

Final Rule: Partial Filling of Prescriptions for Schedule II Controlled Substances (PDF) (July 21, 2023)

Placement of Brorphine in Schedule I; Correction (PDF) (July 19, 2023)

Biopharmaceutical Research Company (PDF) (July 18, 2023)

Restek Corporation (PDF) (July 12, 2023)

Aurobindo Pharma USA, Inc. (PDF) (July 12, 2023)